[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350519-105":3,"doc-detail-350519-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","large-language-model-guided-car-t-in-silico-platform-for-cytokine-optimization-in-liver-cancer-with-low-antigen-density","Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density","","CAR-T cell therapy achieves strong results in hematologic malignancies but is constrained in solid tumors such as liver cancer because antigen heterogeneity, low target antigen density, and an immunosuppressive tumor microenvironment reduce efficacy. Cytokine engineering can enhance CAR-T persistence and function, yet optimal cytokine payloads vary with tumor and microenvironment context, making broad experimental comparisons burdensome. This study applies an LLM-based CAR-T in silico platform to evaluate multiple cytokines and identify IL-15 as the most effective enhancer for GPC3-targeted CAR-T cells, validated in vitro and in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/large-language-model-guided-car-t-in-silico-platform-for-cytokine-optimization-in-liver-cancer-with-low-antigen-density/350519/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/large-language-model-guided-car-t-in-silico-platform-for-cytokine-optimization-in-liver-cancer-with-low-antigen-density/350519.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is CAR-T cell therapy less effective in liver cancer compared with hematologic malignancies?","Question",{"text":63,"@type":64},"Because liver cancer presents antigen heterogeneity, low target antigen density, and an immunosuppressive tumor microenvironment (TME), which limit CAR-T efficacy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the LLM-guided CAR-T in silico platform do in this study?",{"text":68,"@type":64},"It uses LLM-based knowledge synthesis and mechanistic simulation to systematically evaluate cytokine engineering strategies and prioritize cytokines for CAR-T engineering before experimental testing.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cytokine strategy proved most effective, and how was it validated?",{"text":72,"@type":64},"IL-15-engineered GPC3 CAR-T cells showed superior proliferation, persistence, and serial cytotoxicity against GPC3-low liver cancer cells, with improved tumor control in human liver cancer xenograft models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350519,1790928478,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45",8,"Nan et al. Journal of Hematology & Oncology (2026) 19:49 [https://doi.org/10.1186/s13045-026-01822-6](https://doi.org/10.1186/s13045-026-01822-6)  \nJournal of Hematology & Oncology  \nCORRESPONDENCE Open Access  \nLarge language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density  \nHaochen Nan1, Xinyuan Shen1,2,3, Youcheng Yang1, Shubing Wang1 andYan-Ruide Li 1,2,3*  \nAbstract  \nCAR-T cell therapy has shown remarkable success in hematologic malignancies but remains limited in solid tumors such as liver cancer due to antigen heterogeneity, low target antigen density, and an immunosuppressive tumor microenvironment (TME) . Cytokine engineering can enhance CAR-T persistence and effector function; however, the optimal cytokine payload may vary depending on tumor type, target antigen expression level, and microenvironmental context, making systematic experimental comparison time-consuming and labor-intensive. Here, we applied a large language model (LLM)–based CAR-T in silico platform to systematically evaluate cytokine engineering strategies, including IL-2, IL-7, IL-12, IL-15, and IL-18, in glypican-3 (GPC3)–targeted CAR-T cells for liver cancer. We used cytokine selection as a biologically grounded benchmark to test whether the platform could recover known CAR-T cell-relevant cytokine biology and support future novel predictions. Computational predictions identified IL-15 as the most effective enhancer, particularly against tumor cells with low GPC3 expression. Guided by these results, we generated cytokine-armored GPC3 CAR-T cells and performed in vitro and in vivo validation. IL-15-engineered CAR-T cells exhibited superior proliferation, persistence, and serial cytotoxicity against GPC3-low liver cancer cells. In human liver cancer xenograft models, IL-15-enhanced CAR-T cells achieved improved tumor control compared with conventional and other cytokine-engineered CAR-T cells. The recovery of IL-15 served as a positive benchmark supporting the validity of the LLM-guided CAR-T in silico workflow. Collectively, this study establishes an LLM-guided framework, schema-constrained for rational cytokine selection in CAR-T engineering and identifies IL-15 as a potent enhancer for targeting antigen-low liver cancers.  \nKeywords Large language model (LLM), Agent-based modeling, Physics of multicellular biology, Chimeric antigen receptor (CAR), CAR-engineered T (CAR-T) cell, Cytokine engineering, IL-15, Liver cancer, GPC3, Antigen escape.  \n*Correspondence: Yan-Ruide Li [charlie.li@ucla.edu](charlie.li@ucla.edu)  \n1Department of Bioengineering, University of California, Los Angeles 90095, CA, USA  \n2Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles 90095, CA, USA 3Goodman-Luskin Microbiome Center, University of California, Los Angeles 90095, CA, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecom","cbCaillTKR1tWTYf","https://ap.wps.com/l/cbCaillTKR1tWTYf","pdf",1730409,5,"English","# Abstract\n# Introduction\n## CAR-T limitations in solid tumors\n# Methods and Framework\n## LLM-guided cytokine prioritization\n# Computational Predictions and Benchmarks\n## Cytokine functional landscape\n# In Silico and Experimental Validation\n## Tumor control with IL-15-engineered CAR-T\n# Results and Conclusions\n## LLM-guided cytokine selection framework","[{\"question\":\"Why is CAR-T cell therapy less effective in liver cancer compared with hematologic malignancies?\",\"answer\":\"Because liver cancer presents antigen heterogeneity, low target antigen density, and an immunosuppressive tumor microenvironment (TME), which limit CAR-T efficacy.\"},{\"question\":\"What does the LLM-guided CAR-T in silico platform do in this study?\",\"answer\":\"It uses LLM-based knowledge synthesis and mechanistic simulation to systematically evaluate cytokine engineering strategies and prioritize cytokines for CAR-T engineering before experimental testing.\"},{\"question\":\"Which cytokine strategy proved most effective, and how was it validated?\",\"answer\":\"IL-15-engineered GPC3 CAR-T cells showed superior proliferation, persistence, and serial cytotoxicity against GPC3-low liver cancer cells, with improved tumor control in human liver cancer xenograft models.\"}]","Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density | PDF",1790089390,13,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc6ce8e231b2ac49f8afa0228228068c.webp",983,1310,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3e7ea33b68c21abe0fbe809628e043d.webp",982,1309,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78f05588ad51a0b8b295f8f916e26ee0.webp",981,1308,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/756aebfcc9b30b58b17dbd0c8f2f08e9.webp",980,1306,{"code":4,"msg":82,"data":117},[118,122,126,130,134,139,143,146,151,154,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":140,"show_sort_weight":141,"slug":142},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":144,"slug":145},30,"research-report",{"id":147,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":149,"slug":150},9,"Religion & Spirituality",20,"religion-spirituality",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":152,"show_sort_weight":149,"slug":153},"World Cup","world-cup",{"id":155,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":155,"slug":157},10,"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":92,"slug":161},19,"General","general"]